Saturday 17 October 2026
Export BCAB’s income statement to Excel — free account
BioAtla, Inc.
BCAB Healthcare Biotechnology
BioAtla, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 81.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4,233.3%, EPS grew 101.7% and free cash flow grew 97.0%, each against the same quarter a year earlier.
1.36
0.06
+4.62%
Follow BCAB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 118.74% | 275.38% | 543.76% | 1,565.05% |
+8 more TTM periods Free account |
|
| (171.72%) | (216.05%) | (179.95%) | (165.61%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
187.64% | 287.61% | 432.28% | 809.85% | |
Average Days of Receivables |
41.13 | — | — | — | |
Free Cash Flow per Share |
(14.14) | (24.76) | (40.97) | (48.58) | |
Free Cash Flow |
(23.48) | (37.18) | (48.20) | (57.07) | |
| Other line items | |||||
Cash ROIC |
67.69% | 105.19% | 165.81% | 249.04% | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
143.43% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
85.45% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
22.46% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.75 | 0.73 | 0.81 | 0.88 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 3.11 | 1.80 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
10.69 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(14.14) | (24.76) | (40.97) | (48.58) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | — | — |
Columns are period end dates